EMA Says J&J Covid Vaccine's Benefits Outweigh Rare Blood Clot Risks

RTTNews

20 Apr 2021 0 shares 3 views

EMA Says J&J Covid Vaccine's Benefits Outweigh Rare Blood Clot Risks

EMA Says J&J Covid Vaccine's Benefits Outweigh Rare Blood Clot Risks

RTTNews

Published 20 Apr 2021

European Medicines Agency Tuesday said it has found a possible link between the Johnson & Johnson's (JNJ) Covid-19 vaccine and rare blood clots. However, the Europe's medicines regulator pointed out that the overall benefits of getting the vaccine outweigh the risks.

You might like

Related news coverage

An immunologist explains why the benefits of taking the Johnson & Johnson COVID-19 vaccine outweigh the risks

Business Insider 29 Apr 2021

Dr. William Petri advises young women to consider another vaccine, but explains there's no record of people over 50 getting the..

Quebec confirms 1st death related to rare AstraZeneca-linked blood clots, emphasizes benefits outweigh risks
CBC.ca 27 Apr 2021
Continuing to use Johnson & Johnson's vaccine could save 1,400 lives in the next 6 months, the CDC says
Business Insider 27 Apr 2021
California man hospitalized with clot after J&J vaccination
SeattlePI.com 26 Apr 2021
As U.S. Leans On Vaccines To Contain Spread, COVID-19 Surges Elsewhere
Newsy 24 Apr 2021

Advertisement

More coverage

With OK from experts, some states resume use of J&J vaccine

SeattlePI.com 24 Apr 2021

NEW YORK (AP) — With a green light from federal health officials, several states resumed use of the one-shot Johnson & Johnson..

U.S. Resumes Giving Johnson And Johnson Vaccine With Warning
Newsy 24 Apr 2021
EU agency says people should get 2nd dose of AstraZeneca too
SeattlePI.com 23 Apr 2021
US health panel reviews J&J vaccine pause over rare clots
SeattlePI.com 23 Apr 2021
EU agency to issue more guidance on AstraZeneca's COVID shot
SeattlePI.com 23 Apr 2021